1072946-50-9|(6-Chloro-2-methoxypyridin-3-yl)boronic acid| Ambeed

Size	Price	VIP Price	US Stock	Global Stock	In Stock
{[ item.pr_size ]}		Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

{[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

Quality Control of [ 1072946-50-9 ] Purity: 96% SDS Specification

COA

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

NMR

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

CNMR

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

HPLC

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

LC-MS

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

1-2 Day Shipping
High Quality
Technical Support

Product Details of [ 1072946-50-9 ]

CAS No. :	1072946-50-9
Formula :	C₆H₇BClNO₃
M.W :	187.39
SMILES Code :	COC1=NC(Cl)=CC=C1B(O)O
MDL No. :	MFCD11053817
InChI Key :	QMTFZVCHSRMZJW-UHFFFAOYSA-N
Pubchem ID :	46738928

Safety of [ 1072946-50-9 ]

GHS Pictogram:
Signal Word:	Warning
Hazard Statements:	H302
Precautionary Statements:	P280-P305+P351+P338

Computational Chemistry of [ 1072946-50-9 ] Show Less

Physicochemical Properties

Num. heavy atoms	12
Num. arom. heavy atoms	6
Fraction Csp3	0.17
Num. rotatable bonds	2
Num. H-bond acceptors	4.0
Num. H-bond donors	2.0
Molar Refractivity	45.56
TPSA ? Topological Polar Surface Area: Calculated from Ertl P. et al. 2000 J. Med. Chem.	62.58 Å²

Lipophilicity

Log P_o/w (iLOGP)? iLOGP: in-house physics-based method implemented from Daina A et al. 2014 J. Chem. Inf. Model.	0.0
Log P_o/w (XLOGP3)? XLOGP3: Atomistic and knowledge-based method calculated by XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry	1.02
Log P_o/w (WLOGP)? WLOGP: Atomistic method implemented from Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.	-0.58
Log P_o/w (MLOGP)? MLOGP: Topological method implemented from Moriguchi I. et al. 1992 Chem. Pharm. Bull. Moriguchi I. et al. 1994 Chem. Pharm. Bull. Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.	-0.57
Log P_o/w (SILICOS-IT)? SILICOS-IT: Hybrid fragmental/topological method calculated by FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com	-0.55
Consensus Log P_o/w? Consensus Log P_o/w: Average of all five predictions	-0.13

Water Solubility

Log S (ESOL):? ESOL: Topological method implemented from Delaney JS. 2004 J. Chem. Inf. Model.	-1.88
Solubility	2.46 mg/ml ; 0.0131 mol/l
Class? Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly	Very soluble
Log S (Ali)? Ali: Topological method implemented from Ali J. et al. 2012 J. Chem. Inf. Model.	-1.92
Solubility	2.23 mg/ml ; 0.0119 mol/l
Class? Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly	Very soluble
Log S (SILICOS-IT)? SILICOS-IT: Fragmental method calculated by FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com	-1.66
Solubility	4.09 mg/ml ; 0.0218 mol/l
Class? Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly	Soluble

Pharmacokinetics

GI absorption? Gatrointestinal absorption: according to the white of the BOILED-Egg	High
BBB permeant? BBB permeation: according to the yolk of the BOILED-Egg	No
P-gp substrate? P-glycoprotein substrate: SVM model built on 1033 molecules (training set) and tested on 415 molecules (test set) 10-fold CV: ACC=0.72 / AUC=0.77 External: ACC=0.88 / AUC=0.94	No
CYP1A2 inhibitor? Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set) and tested on 3000 molecules (test set) 10-fold CV: ACC=0.83 / AUC=0.90 External: ACC=0.84 / AUC=0.91	No
CYP2C19 inhibitor? Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set) and tested on 3000 molecules (test set) 10-fold CV: ACC=0.80 / AUC=0.86 External: ACC=0.80 / AUC=0.87	No
CYP2C9 inhibitor? Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set) and tested on 2075 molecules (test set) 10-fold CV: ACC=0.78 / AUC=0.85 External: ACC=0.71 / AUC=0.81	No
CYP2D6 inhibitor? Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set) and tested on 1068 molecules (test set) 10-fold CV: ACC=0.79 / AUC=0.85 External: ACC=0.81 / AUC=0.87	No
CYP3A4 inhibitor? Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set) and tested on 2579 molecules (test set) 10-fold CV: ACC=0.77 / AUC=0.85 External: ACC=0.78 / AUC=0.86	No
Log Kp (skin permeation)? Skin permeation: QSPR model implemented from Potts RO and Guy RH. 1992 Pharm. Res.	-6.72 cm/s

Druglikeness

Lipinski? Lipinski (Pfizer) filter: implemented from Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev. MW ≤ 500 MLOGP ≤ 4.15 N or O ≤ 10 NH or OH ≤ 5	0.0
Ghose? Ghose filter: implemented from Ghose AK. et al. 1999 J. Comb. Chem. 160 ≤ MW ≤ 480 -0.4 ≤ WLOGP ≤ 5.6 40 ≤ MR ≤ 130 20 ≤ atoms ≤ 70	None
Veber? Veber (GSK) filter: implemented from Veber DF. et al. 2002 J. Med. Chem. Rotatable bonds ≤ 10 TPSA ≤ 140	0.0
Egan? Egan (Pharmacia) filter: implemented from Egan WJ. et al. 2000 J. Med. Chem. WLOGP ≤ 5.88 TPSA ≤ 131.6	0.0
Muegge? Muegge (Bayer) filter: implemented from Muegge I. et al. 2001 J. Med. Chem. 200 ≤ MW ≤ 600 -2 ≤ XLOGP ≤ 5 TPSA ≤ 150 Num. rings ≤ 7 Num. carbon > 4 Num. heteroatoms > 1 Num. rotatable bonds ≤ 15 H-bond acc. ≤ 10 H-bond don. ≤ 5	1.0
Bioavailability Score? Abbott Bioavailability Score: Probability of F > 10% in rat implemented from Martin YC. 2005 J. Med. Chem.	0.55

Medicinal Chemistry

PAINS? Pan Assay Interference Structures: implemented from Baell JB. & Holloway GA. 2010 J. Med. Chem.	0.0 alert
Brenk? Structural Alert: implemented from Brenk R. et al. 2008 ChemMedChem	2.0 alert: heavy_metal
Leadlikeness? Leadlikeness: implemented from Teague SJ. 1999 Angew. Chem. Int. Ed. 250 ≤ MW ≤ 350 XLOGP ≤ 3.5 Num. rotatable bonds ≤ 7	No; 1 violation:MW<1.0
Synthetic accessibility? Synthetic accessibility score: from 1 (very easy) to 10 (very difficult) based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties, trained on 12'782'590 molecules and tested on 40 external molecules (r² = 0.94)	2.33

Application In Synthesis of [ 1072946-50-9 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

Downstream synthetic route of [ 1072946-50-9 ]

[ 1072946-50-9 ] Synthesis Path-Downstream 1~27

1
[ 1007882-59-8 ]
[ 1072946-50-9 ]
[ 1255936-29-8 ]

Yield	Reaction Conditions	Operation in experiment
		To a solution of compound Int-lla (0.5 g, 1.58 mmol, prepared as described in U.S. Patent Publication No. US20090068140) in DME (15 mL) at room temperature under N2 was added PdCl2(dppf)2 (258 mg, 0.30 mmol). The reaction mixture was allowed to stir at 100 0C for 5 minutes, then a solution of compound Int-llb (592 mg, 3.16 mmol) and K2CO3 (654 mg, 4.74 mmol) in 15 mL H2O was added to the reaction mixture in 3 portions over 10 minutes. The resulting reaction was allowed to stir for an additional 30 minutes, after which time thin-layer chromatography analysis indicated consumption of compound Int-7a. The reaction was allowed to stir for an additional 30 minutes, then was concentrated in vacuo, and the residue obtained was taken up in 150 mL ethyl acetate. The organic phase was separated, washed with water (50 mL), brine and dried over sodium sulfate. After filtration, the organic layer was concentrated in vacuo and the resulting residue was purified using flash liquic chromatography (0% to 100% EtOAc/Hexane) to provide 600 mg of compound Int-llc (>; 85% purity, theory 597 mg). HPLC (C18 column Gemini 5u HOA, 150X21.2 mm, 5 micron). FABMS: MH+ = 379
		To a solution of Compound Int-7d (0.5 g, 1.58 mmol) in DME (15 mL) at room temperature under N2 was added PdCl2(dppf)2 (258 mg, 0.30 mmol). The reaction mixture was allowed to stir at 100 0C for 5 minutes, then a solution of compound Int-19a (592 mg, 3.16 mmol) and K2CO3 (654 mg, 4.74 mmol) in 15 mL H2O was added to the reaction mixture in 3 portions over 10 minutes. The resulting reaction was allowed to stir for an additional 30 minutes, after which time thin-layer chromatography analysis indicated consumption of compound Int-7a. The reaction was allowed to stir for an additional 30 minutes, then was concentrated in vacuo, and the residue obtained was taken up in 150 niL ethyl acetate. The organic phase was separated, washed with water (50 rnL), brine and dried over sodium sulfate. After filtration, the organic layer was concentrated in vacuo and the resulting residue was purified using flash liquic chromatography (0% to 100% EtOAc/Hexane) to provide 600 mg of compound Int-19b (>; 85% purity, theory 597 mg). HPLC (C18 column Gemini 5u HOA, 150X21.2 mm, 5 micron). FABMS: MH+ = 379

References: [1]Patent: WO2010/132538,2010,A1 .Location in patent: Page/Page column 108-109.
[2]Patent: WO2010/138791,2010,A1 .Location in patent: Page/Page column 101-102.

2
[ 1072946-50-9 ]
[ 17228-64-7 ]

References: [1]Journal of Organic Chemistry,2015,vol. 80,p. 9807 - 9816.

3
[ 1072946-50-9 ]
2-chloro-6-methoxypyridine-5-d [ No CAS ]

References: [1]Journal of Organic Chemistry,2015,vol. 80,p. 9807 - 9816.

4
[ 1007882-59-8 ]
[ 1072946-50-9 ]
[ 1255936-29-8 ]

Yield	Reaction Conditions	Operation in experiment
		EXAMPLE 15 Preparation of Intermediate Compound Int-15c (0321) (0322) To a solution of compound Int-7d (0.5 g, 1.58 mmol) in DME (15 mL) at room temperature under N2 was added PdCl2(dppf)2 (258 mg, 0.30 mmol). The reaction mixture was allowed to stir at 100 C for 5 minutes, then a solution of compound Int-15b (592 mg, 3.16 mmol) and K2CO3 (654 mg, 4.74 mmol) in 15 mL H2O was added to the reaction mixture in 3 portions over 10 minutes. The resulting reaction was allowed to stir for an additional 30 minutes, after which time thin-layer chromatography analysis indicated consumption of compound Int-7a. The reaction was allowed to stir for an additional 30 minutes, then was concentrated in vacuo, and the resulting residue was taken up in 150 mL ethyl acetate. The organic phase was separated, washed with water (50 mL), brine and dried over sodium sulfate. After filtration, the organic layer was concentrated in vacuo and the resulting residue was purified using flash liquid chromatography (0% to 100% EtOAc/Hexane) to provide 600 mg of compound Int-15c (> 85% purity, theory 597 mg). HPLC (C18 column Gemini 5u 110A, 150X21.2 mm, 5 micron). FABMS: MH+ = 379

References: [1]Patent: EP2545060,2015,B1 .Location in patent: Paragraph 0321; 0322.

5
[ 1072946-50-9 ]
1-(2-[{(1H-pyrazol-3-yl)}oxymethyl]-3-methylphenyl)-4-methyl-1,4-dihydrotetrazole-5-one [ No CAS ]
1-(2-[1-(6-chloro-2-methoxypyridin-3-yl)-1H-pyrazol-3-yl]oxymethyl}-3-methylphenyl)-4-methyl-1,4-dihydrotetrazol-5-one [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
0.075 g	With pyridine; copper diacetate; In acetonitrile; for 6h;Molecular sieve; Reflux;	Production Example 1 (0478) A mixture of 0.5 g of 1-(2-[{(1H-pyrazol-3-yl)}oxymethyl]-3-methylphenyl)-4-methyl-1,4-dihydrotetrazol-5-one mentioned in Reference Production Example 26, 0.4 g of <strong>[1072946-50-9]6-chloro-2-methoxypyridine-3-boronic acid</strong>, 0.48 g of copper(II) acetate, 0.75 g of Molecular Sieves 4A, 0.3 mL of pyridine, and 5 mL of acetonitrile was stirred with heating under reflux for 6 hours. After cooling, the reaction mixture was filtered and the filtrate was concentrated under reduced pressure. The residue thus obtained was subjected to silica gel column chromatography to obtain 0.075 g of 1-(2-[1-(6-chloro-2-methoxypyridin-3-yl)-1H-pyrazol-3-yl]oxymethyl}-3-methylphenyl)-4-methyl-1,4-dihydrotetrazol-5-one (hereinafter referred to as the present compound 1). (0479) 1H-NMR (CDCl3) delta: 8.05-8.02 (2H, m), 7.40-7.37 (2H, m), 7.27-7.24 (1H, m), 7.01 (1H, d, J=8.2 Hz), 5.80 (1H, d, J=2.7 Hz), 5.30 (2H, s), 4.06 (3H, s), 3.64 (3H, s), 2.54 (3H, s).
0.075 g	With pyridine; copper diacetate; In acetonitrile; for 6h;Molecular sieve; Reflux;	The 0.5g of 1- (2 - [{(1H- pyrazol-3-yl) oxy} methyl] -3-methyl-phenyl) -4-methyl-1,4-dihydro-tetrazol - 5-one (prepared in reference Example 26 mentioned), 0.4g of 6-chloro-2-methoxy-3-boronic acid, 0.48g of copper acetate (II), 0.75g of molecular sieve 4A, 0.3mL of mixture of pyridine and 5mL of acetonitrile was heated under reflux for 6 hours with stirring. After cooling, the reaction mixture was filtered and the filtrate was concentrated under reduced pressure. The thus obtained residue was subjected to silica gel column chromatography to obtain 0.075 g of 1- (2 - [1- (6-chloro-2-methoxy-pyridin-3-yl) lH-pyrazol-3-yl ] oxy} methyl 3-methylphenyl) -4-methyl-1,4-dihydro-tetrazol-5-one (hereinafter referred to as the present compound 1).

References: [1]Patent: US2016/174558,2016,A1 .Location in patent: Paragraph 0478; 0479.
[2]Patent: CN105408322,2016,A .Location in patent: Paragraph 0766; 0767; 0768; 0769; 0770.

6
[ 1072946-50-9 ]
1-(2-[{(1H-pyrazol-3-yl)}oxymethyl]-3-methylphenyl)-4-methyl-1,4-dihydrotetrazole-5-one [ No CAS ]
1-(2-[1-(6-chloro-2-methoxypyridin-3-yl)-1H-pyrazol-3-yl]oxymethyl}-3-methylphenyl)-4-methyl-1,4-dihydrotetrazole-5-thione [ No CAS ]

References: [1]Patent: US2016/174558,2016,A1 .

7
[ 1072946-50-9 ]
1-(2-[{(1H-pyrazol-3-yl)}oxymethyl]-3-methylphenyl)-4-methyl-1,4-dihydrotetrazole-5-one [ No CAS ]
3-[(2-amino-6-methylphenyl)methyloxy]-1-(6-chloro-2-methoxypyridin-3-yl)pyrazole [ No CAS ]

References: [1]Patent: CN105408322,2016,A .

8
[ 15862-37-0 ]
[ 1072946-50-9 ]
5-bromo-6’-chloro-2’-methoxy-3-nitro-2,3’-bipyridine [ No CAS ]